IP Library Granted Patent US 8,501,817
Granted Patent B2
US 8,501,817 · App. 12/401,812 · Granted Aug 6, 2013

Stabilized compositions of alkylating agents and methods of using same

Inventors: Robert Alonso (Rye, NH); Barry R. Walker (Bryn Mawr, PA); Peter A. Crooks (Nicholasville, KY)
Assignee: Ceptaris Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,501,817
App. No.
12/401,812
Granted
Aug 6, 2013
Kind
B2
Abstract

A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol does not include petrolatum or ethanol. The method comprises topically applying the composition of the alkylating agent to the affected skin, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum or ethanol.

Claims (14)

1. A composition for treating a skin disorder, comprising:

a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier, wherein the non-aqueous vehicle or carrier comprises between about 15% and about 60% by weight of a pharmaceutically acceptable excipient, wherein the Nitrogen Mustard is represented by the following structures:

wherein each R 1 , R 2 , R 3 . . . R 34 (R 1 -R 34 ) is independently selected from the group consisting of H, a linear alkyl group having 1-6 carbon atoms, a branched alkyl group having 2-12 carbon atoms, a cycloalkyl group having 3-17 carbon atoms, a fluorinated linear alkyl group having 2-12 carbon atoms, a fluorinated branched alkyl group having 2-12 carbon atoms, a fluorinated cycloalkyl group having 3-17 carbon atoms, aryl groups, aralkyl groups, alkaryl groups, cycloalkyl groups, bicycloalkyl groups, alkenyl groups, alkalkenyl groups, alkenylalkyl groups, alkynyl groups, alkalkynyl groups, alkynylalkyl groups, trifluoropropyl groups, cyanopropyl groups, acryloyl groups, arylacryloyl groups, acryloylaryl groups, alkylacyl groups, arylacyl groups, alkylenylacyl groups and alkynylacyl groups, wherein n is 1-3, wherein p is 0-2, wherein n +P<3, wherein any two R 1 -R 34 in the same molecule may be linked to form a three-to eight-membered cyclic group, wherein the pharmaceutically acceptable excipient is 2-(2-ethoxyethoxy) ethanol, and wherein when the composition is applied topically to the skin, there is no clinically significant systemic absorption of the topically applied Nitrogen Mustard.

2. The composition of claim 1 , wherein an ingredient of the non-aqueous vehicle or carrier is selected from the group consisting of, Hydroxypropylcellulose, buffer gel, Menthol Crystals USP5, Butylated Hydroxytoluene NF, Glycerin USP, Edetate Disodium USP, Decyl Methyl Sulfoxide, Kris-Ester 236, polyethylene glycol (PEG), ethylene glycol (EG), polypropylene glycol (PPG), propylene glycol (PG), diethylene glycol monosubstituted ether (DGMSE), HOCH 2 CH 2 OCH 2 CH 2 OR 79 , wherein R 79 is selected from the group consisting of a linear alkyl group having 1-6 carbon atoms, a branched alkyl group having 2-12 carbon atoms, a cycloalkyl group having 3-17 carbon atoms, a fluorinated linear alkyl group having 2-12 carbon atoms, a fluorinated branched alkyl group having 2-12 carbon atoms, a fluorinated cycloalkyl group having 3-17 carbon atoms, an aryl group, an aralkyl group, an alkaryl group, a cycloalkyl group, a bicycloalkyl group, an alkenyl group, an alkalkenyl group, an alkenylalkyl group, an alkynyl group, an alkalkynyl group, an alkynylalkyl group, a trifluoropropyl group, a cyanopropyl group, an acryloyl group, an arylacryloyl group, an acryloylaryl group, an alkylacyl group, an arylacyl group, an alkylenylacyl group, an alkynylacyl group, and combinations thereof.

3. The composition of claim 1 , wherein the non-aqueous vehicle or carrier comprises propylene glycol USP.

4. The composition of claim 1 , further comprising:

Hydroxypropylcellulose, Menthol Crystals USP, Butylated Hydroxytoluene NF, Glycerin USP, Edetate Disodium USP, Decyl Methyl Sulfoxide, or Kris-Ester 236, or any combination thereof.

5. The composition of claim 1 , comprising the HX salt of the Nitrogen Mustard, wherein the HX salt of the Nitrogen Mustard is Nitrogen Mustard.HCl, Nitrogen Mustard.HNO 3 , Nitrogen Mustard.H 2 SO 4 , Nitrogen Mustard.HBr, Nitrogen Mustard.HI, or any combination thereof.

6. The composition of claim 1 , comprising from about 0.0001 to about 2.0 percent by weight of the Nitrogen Mustard or its HX salt.

7. The composition of claim 1 , comprising from about 0.015 to about 0.030 percent by weight of the Nitrogen Mustard of its HX salt.

8. The composition of claim 1 , comprising from about 0.01 to about 0.04 percent by weight of the Nitrogen Mustard or its HX salt.

9. The composition of claim 1 , comprising the Nitrogen Mustard.

10. The composition of claim 1 , comprising the HX salt of the Nitrogen Mustard.

11. The composition of claim 1 , wherein the clause: when the composition is applied topically to the skin, there is no clinically significant systemic absorption of the topically applied Nitrogen Mustard; means there is 0% systemic toxicities.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2023
From: HAMILTON SA LLC
To: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 064961/0567 →
SECURITY INTEREST Recorded Dec 30, 2022
From: HELSINN HEALTHCARE SA; HELSINN THERAPEUTICS (U.S.), INC.; HELSINN BIREX PHARMACEUTICALS LIMITED
To: HAMILTON SA LLC
Reel/Frame 062254/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2020
From: ACTELION PHARMACEUTICALS LTD
To: HELSINN BIREX PHARMACEUTICALS LIMITED
Reel/Frame 051542/0741 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2014
From: CEPTARIS THERAPEUTICS, INC.
To: ACTELION PHARMACEUTICALS, LTD.
Reel/Frame 031896/0320 →
CHANGE OF NAME Recorded Feb 24, 2012
From: YAUPON THERAPEUTICS, INC.
To: CEPTARIS THERAPEUTICS, INC.
Reel/Frame 027757/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2011
From: ALONSO, ROBERT; WALKER, BARRY R.; CROOKS, PETER A.
To: YAUPON THERAPEUTICS, INC.
Reel/Frame 027305/0279 →
Continuity (5)
Continuation In Part 11369305 · Mar 7, 2006
Provisional Application 61039840 · Mar 27, 2008
Provisional Application 60661356 · Mar 14, 2005
Provisional Application 60751128 · Dec 16, 2005
Related Publication 20100029783A9 · Feb 4, 2010